Squalamine prevents motor and non-motor symptoms in the paraquat and lectin rat model of the body-first subtype of Parkinson's disease
Authors:
- Caroline C SwainCSCaroline C Swain
- Vaibhavi V PeshattiwarVPVaibhavi V Peshattiwar
- Dipesh PokharelDipesh Pokharel
- Khoi LeKLKhoi Le
- Isabel KennedyIKIsabel Kennedy
- Denise BarbutDBDenise Barbut
- Michael ZasloffMZMichael Zasloff
- Thyagarajan SubramanianTSThyagarajan Subramanian
- Kala VenkiteswaranKVKala Venkiteswaran
Open Access
- 6 November 2026
- journal article
- Published by SAGE Publications in Journal of Parkinson’s Disease
Abstract
Increasing evidence supports the existence of a distinct body-first subtype of Parkinson's disease (PD), in which the initial site of pathology is in the gut. Animal models that recapitulate the body-first subtype of PD are needed. We tested the hypothesis that non-motor features of the body-first subtype of PD are recapitulated in the paraquat and lectin (P + L) rat model of PD, a model that has previously demonstrated the pathological motor progression of this subtype of PD. Then, we tested whether oral squalamine, a gastrointestinal prokinetic that has been shown to reduce formation of pathological α-synuclein, could prevent pathology, motor, and non-motor findings. Rats (n = 93) were orally gavaged for seven days with paraquat (1 mg/kg) and lectin (0.05%) in 1% sucrose solution. A subset of rats (n = 37) were given 30 days of squalamine (20 mg/kg) in their drinking water immediately following P + L treatment. Rats were tested for parkinsonian motor deficits, gastrointestinal dysmotility, sleep abnormalities, and cognitive deficits. Rats were euthanized and their brains processed for phospho-S 129 -α-synuclein pathology and neurodegeneration. We show that the P + L rat model recapitulates non-motor features and pathology of gastrointestinal dysmotility and sleep abnormalities seen in the body-first subtype of PD. We show that oral squalamine prevents motor deficits, gastrointestinal dysmotility, and sleep abnormalities, and diminishes phospho-S 129 -α-synuclein pathology and neurodegeneration in the nigrostriatal pathway. We show that the P + L rat model recapitulates many features of the body-first subtype of PD and provides pre-clinical evidence for the use of squalamine to mitigate progression in the body-first subtype of PD.Keywords
Funding Information
- DoD NETP (13204752)
- NIH (R01 DK124098)
- University of Toledo startup funds
- Gladfelter foundation
This publication has 81 references indexed in Scilit:
- The natural history of body-first versus brain-first Parkinson’s disease subtypesJournal of Neurology, 2025
- Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in ratsActa Neuropathologica, 2014
- Apolipoprotein D mediates autocrine protection of astrocytes and controls their reactivity level, contributing to the functional maintenance of paraquat-challenged dopaminergic systemsGlia, 2011
- Clinical progression in Parkinson disease and the neurobiology of axonsAnnals of Neurology, 2010
- Primary afferent neurons intrinsic to the guinea-pig intestine, like primary afferent neurons of spinal and cranial sensory ganglia, bind the lectin, IB4Cell and tissue research, 2005
- Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy imagesCytometry Part A, 2004
- Binding of FITC-labelled lectins to the gastrointestinal epithelium of the ratPathology and Oncology Research, 2000
- Cognitive deficits in Parkinson’s diseaseJournal of Neurology, 1996
- Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopaMovement Disorders, 1996
- A light and electron microscopic study of the intraneuronal transport of horseradish peroxidase and wheat germ agglutinin-peroxidase conjugates in the rat visual systemJournal of Neurocytology, 1981